Maraviroc

Generic Name: Maraviroc

Brand Names: Celsentri, Selzentry

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₄₁F_₂N_₅O

CAS Number: 376348-65-1

Unique Ingredient Identifier: MD6P741W8A

Background: Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.

Indication: Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions: CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

Phase 4

Completed

Conditions: AIDS

Interventions: Drug: Maraviroc
Drug: Placebo
Drug: Vardenafil

First Posted Date: 2009-03-02

Last Posted Date: 2013-01-25

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 18

Registration Number: NCT00853840

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

Completed

Conditions: HIV-1

Interventions: Drug: maraviroc

First Posted Date: 2009-02-25

Last Posted Date: 2012-11-07

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 79

Registration Number: NCT00850395

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

Phase 3

Completed

Conditions: HIV Infection
Cardiovascular Disease
HIV Infections
Inflammation

Interventions: Drug: placebo
Drug: Maraviroc

First Posted Date: 2009-02-16

Last Posted Date: 2014-07-24

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 52

Registration Number: NCT00844519

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Phase 2

Completed

Conditions: Human Immunodeficiency Virus-1

Interventions: Drug: maraviroc

First Posted Date: 2009-01-22

Last Posted Date: 2012-06-15

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 129

Registration Number: NCT00827112

Locations: 🇪🇸
Pfizer Investigational Site, Sevilla, Spain

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Raltegravir
Drug: Tenofovir/Emtricitabine
Drug: Maraviroc

First Posted Date: 2008-12-15

Last Posted Date: 2020-01-31

Lead Sponsor: Germans Trias i Pujol Hospital

Target Recruit Count: 30

Registration Number: NCT00808002

Locations: 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

Conditions: HIV

First Posted Date: 2008-12-03

Last Posted Date: 2011-07-25

Lead Sponsor: ViiV Healthcare

Registration Number: NCT00801515

Locations: 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada

Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1

Phase 2

Completed

Conditions: HIV-1

Interventions: Drug: maraviroc

First Posted Date: 2008-11-21

Last Posted Date: 2015-01-26

Lead Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Target Recruit Count: 10

Registration Number: NCT00795444

Locations: 🇪🇸
Hospital Universitario Ramon Y Cajal, Madrid, Spain

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Phase 2

Conditions: Human Immunodeficiency Virus

Interventions: Drug: Maraviroc

First Posted Date: 2008-11-14

Last Posted Date: 2020-04-28

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 103

Registration Number: NCT00791700

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Medical Center of Dallas, Dallas, Texas, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States

and more 38 locations

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Phase 4

Withdrawn

Conditions: Hepatitis B
Human Immunodeficiency Virus
Hepatitis C, Chronic

Interventions: Drug: etravirine
Drug: maraviroc

First Posted Date: 2008-10-31

Last Posted Date: 2012-01-19

Lead Sponsor: ViiV Healthcare

Registration Number: NCT00782301

Locations: 🇵🇱
Pfizer Investigational Site, Bydgoszcz, Poland

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-03716539
Drug: Darunavir
Drug: Midazolam
Drug: Maraviroc
Other: Placebo
Drug: Midazolam + PF-03716539 (100 mg)
Drug: Maraviroc +PF-03716539
Drug: Darunavir + PF-03716539
Drug: Midazolam + PF-03716539 (50 mg)

First Posted Date: 2008-10-31

Last Posted Date: 2009-06-02

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT00783484

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy